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ABSTRAK 
 
Kami melaporkan dua kes leukemia akut bifenotipik yang didiagnos di Hospital Universiti 
Kebangsaan Malaysia (HUKM), ciri-ciri klinikal, hematologi dan tindakbalas penyakit ini 
terhadap kemoterapi. Kedua-dua pesakit adalah wanita pertengahan umur yang 
menunjukkan pembengkakan hati dan limpa serta bilangan sel darah putih yang tinggi.  
Sum-sum tulang menunjukkan kepadatan sel dimana 90% terdiri dari sel-sel leukemia 
pelbagai saiz. Analisa sitokimia menunjukkan lebih daripada 3% adalah positif terhadap 
ujian peroksidase dan sel-sel leukaemia yang lebih kecil menunjukkan positiviti secara 
blok terhadap ujian periodic acid-schiff (PAS).  Ujian imunofenotip menunjukkan ko-
ekspresi dwi penanda sel CD 33 dan CD 19, CD 19 dan CD34, intra CD22, intra TdT dan 
intraMPO.  Analisa sitogenetik daripada salah seorang pesakit tersebut menunjukkan 
kehadiran kromosom Philadelphia  yang disahkan dengan ujian Fluorescence In Situ 
Hybridisation (FISH). Analisa molekular juga menunjukkan kehadiran protein fusi BCR-
ABL.  Kedua-dua pesakit menerima rawatan kemoterapi yang terdiri daripada daunorubicin 
dan cytosine arabinoside. Namun begitu, pesakit yang mempunyai kromosom Philadelphia 
BCR-ABL tidak berjaya mencapai remisi morfologi selepas kemoterapi induksi. 
Memandangkan prognosis buruk pesakit leukemia ini,  pemindahan sel-sel stem periferi 
dirancangkan untuk kedua-dua pesakit ini. 
 
Kata kunci:  leukemia akut bifenotipik, immunofenotip, faktor-faktor prognosis, sitogenetik, 
rawatan kemoterapi 
 
 
ABSTRACT 
 
We report two cases of biphenotypic acute leukaemia diagnosed in Hospital Universiti 
Kebangsaan Malaysia (HUKM), their clinical, haematological characteristics and response 
to chemotherapy. Both patients are middle-aged ladies who presented with 
hepatosplenomegaly and high white cell count, mainly composed of blast cells. Their bone 
marrow aspirations were hypercellular comprising of more than 90% heterogenous blast 
cells. Cytochemical analyses show  more than 3% positivity towards peroxidase, with 
smaller blasts showing block positivity towards PAS. Immunophenotypically, the blasts 
showed dual expression of CD 33 and CD 19, CD 19 and CD34, intra CD22, intra TdT and 
intraMPO. One of the patients showed presence of the Philadelphia chromosome on 
cytogenetic analysis which was confirmed by Fluorecsence In Situ Hybridisation (FISH). 
Molecular analysis also showed presence of the BCR-ABL fusion protein. Both patients 
were given combination chemotherapy consisting of daunorubicin and cytosine 
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arabinoside.However, the patient with positive Philadelphia chromosome BCR-ABL did not 
achieve morphological remission after induction chemotherapy. In view of the poor 
prognosis of this disease, both the patients were planned for upfront peripheral blood stem 
cell transplantation. 
 
Keywords:  biphenotypic acute leukaemia, immunophenotyping, prognostic factors, 
cytogenetic, treatment 
 
 
 
INTRODUCTION 
 
Biphenotypic acute leukaemia (BAL) is a 
rare disease, which occurs in 5 to 10% of 
acute leukaemias. BAL can arise de novo 
or it may be secondary to previous 
cytotoxic therapy. As with other types of 
acute leukaemia, patients with BAL usually 
present with symptoms resulting from 
cytopenias. The blast count at diagnosis 
does not differ from that in acute myeloid 
leukemia (AML) or acute lymphoid 
leukaemia (ALL). BAL can present at any 
age, including children, although it is more 
common in adults. The blasts cell 
morphology are variable; some cells may 
display myeloid differentiating features 
such as azurophilic granules or Auer rods; 
others may have lymphoid or 
undifferentiated morphology. In some 
cases, two blast populations may be seen, 
consisting of a population resembling 
myeloblast with another population of 
smaller lymphoid-looking blasts. 
Immunophenotyping is mandatory to 
establish the diagnosis of BAL. These 
blasts co-express myeloid and T or B 
lineage specific antigens. Diagnosis is 
based on a scoring system adopted by the 
European Group of Immunological 
Classification of Leukaemias (EGIL) (Bene 
et al 1995), and it has been included in the 
WHO classification of haemopoietic 
malignancies as acute leukaemia of 
ambiguous lineage (Brunning et al 2001). 
There is no specific cytogenetic 
abnormality in BAL. Studies done by 
Carbonell F et al (1996) had shown that the 
most common cytogenetic abnormalities 
were t(9;22)(q34;q11) and abnormalities of 
chromosome 11, particularly 11q23. BAL is 
very difficult to treat with many cases being 
resistant to induction chemotherapy; and 
those which achieved morphological 
remission had a higher risk of relapse. The 
prognosis of BAL in adults is worse than 
AML or ALL and most are associated with 
over-expression of P glycoprotein (Pgp) 
(Legrand et al 1993).  
 
CASE REPORT 
 
CASE 1 
 
AS, a 45-year-old policewoman was 
admitted to HUKM with severe back pain of 
one day.  She also gave a history of loss of 
appetite and loss of weight of two months 
duration. She was diagnosed to have 
hypertension, ischaemic heart disease and 
hyperlipidaemia. On physical examination, 
she was pale, with enlarged liver and 
spleen. No lymph node enlargement or 
hypertrophy of the gums was observed. No 
bleeding tendency was noted. Vital signs 
were stable. Examination of other systems 
were normal. Laboratory investigation and 
results are shown in Table 1. 
The patient was given induction 
chemotherapy consisting of cytosine 
arabinoside for seven days and 
daunurobicin for three days. Bone marrow 
assessment at day 28 post chemotherapy 
showed that she has achieved marrow 
remission. She was given the same regime 
for her first consolidation treatment and for 
her second and third consolidation; the 
chemotherapy regimen was changed to 
mitoxantrone for two days and cytosine 
arabinoside for four days. Throughout the 
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post chemotherapy period, she developed 
severe myelosuppression with neutropenic 
sepsis, thrombocytopenia and anaemia. 
She was planned for allogeneic peripheral 
blood stem cell transplantation but while 
waiting for the work out, she had a relapse. 
She was then given salvage chemotherapy 
which consists of Fludarabine, cytosine 
arabinoside and idarubicin (FLAG-IDA) 
with growth factor support.  Unfortunately, 
10 days post chemotherapy, she 
developed severe neutropenic sepsis with 
shock and she succumbed to her death. 
 
CASE 2 
 
RO, a 30-year-old Malay lady was referred 
to HUKM from Putrajaya Hospital with a 
history of fever of two weeks duration, 
blurring of vision of her left eye, fatigue and 
lethargy.  On admission, she was very pale. 
There were multiple ulcers over her lips 
and palate, and she had gum hypertrophy. 
Multiple bilateral cervical lymphadenopathy 
were also noted. Vital signs were stable. 
Fundus examination showed presence of 
left retinal haemorrhages with dilated 
vessels. Cardiovascular and respiratory 
systems were normal. Abdominal 
examination showed hepatosplenomegaly 
measuring 4 cm and 3 cm below the costal 
margins respectively. Laboratory 
investigations and results are shown in 
Table 1. 
This patient was also given induction 
chemotherapy consisting of cytosine 
arabinoside for seven days and 
daunorubicin for three days. In the post 
chemotherapy period, the patient 
developed persistent pancytopenia, 
complicated with neutropenic sepsis. A 
month after chemotherapy, her peripheral 
blood showed presence of residual blasts. 
Bone marrow aspiration confirmed the 
persistence of disease. A second induction 
chemotherapy was started with a regimen 
consisting of cyclophosphamide, 
dexamethasone, doxorubicin and 
vincristine. However, during chemotherapy, 
she developed severe upper gastro-
intestinal bleeding and succumbed to death. 
 
TABLE 1: Laboratory findings in two cases of 
Biphenotypic Acute Leukemia (BAL) 
 
 CASE 1 CASE 2 
FBC WBC: 37.4 x 109/l 
Hb: 9.2g/dl 
Platelets: 54 x 109/l 
WBC: 123 x 109/l 
Hb: 5.4g/dl 
Platelets: 63 x 109/l 
Peripheral blood 
smear 
Heterogenous 
population of blast 
cells (> 90%) 
Heterogenous 
population of blast 
cells (> 90%) 
Bone marrow 
aspiration 
Hypercellular 
marrow  
(> 90% blasts).  
Heterogenous 
population of blasts 
(Fig. 1): 
i.  Large blasts: 
abundant to 
moderate 
cytoplasm, 
prominent 
nucleoli   
 
ii.  Small blasts: 
high N/C ratio, 
inconspicuous 
nucleoli.   
Hypercellular 
marrow  
(> 90% blasts).   
Heterogenous 
population of blasts 
(Fig. 2): 
i.  Large blasts: 
abundant 
cytoplasm with 
azurophilic 
granules, 
prominent 
nucleoli 
ii. Small blasts: 
high N/C ratio, 
scanty basophilic 
cytoplasm, 
indistinct nucleoli  
Cytochemistry of 
bone marrow 
Large blast cells are 
mainly positive for 
peroxidase and 
some small blasts 
are positive for PAS 
(block positivity) 
Some blasts are 
positive with 
peroxidase stain, 
some are positive 
with non-specific 
esterase and some 
with specific 
esterase. Some of 
the blasts also 
showed block 
positivity with PAS 
stain. 
Immunophenotyping Gated cells co-
expressed CD 19 
and CD33, CD 13 
and CD10, HLA DR 
and CD34, intra 
TdT, intra22 and 
intraMPO (Fig. 3) 
Gated cells co-
expressed CD 19 
and CD33, CD 13 
and CD10, HLA DR 
and CD34, intra 
TdT, intra22 and 
intraMPO 
Cytogenetic analysis 
(FISH) 
Unsatisfactory Presence of 
Philadelphia 
chromosome     
(Fig. 4) 
Molecular analysis No BCR-ABL 
fragment detected 
Major BCR-ABL 
fragment detected 
(Fig. 5).   
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FIGURE 1:  Bone marrow aspiration of case 1 showing a heterogenous population of large 
(red arrow) and small (blue arrow) blasts cells. (MGG stain x 400) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: Bone marrow aspiration of case 2 showing a heterogenous population of large 
(red arrow) and small (blue arrow) blast cells. (MGG stain x 400) 
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FIGURE 3: Immunophenotyping of case 1 show
13 and CD10, HLA DR and CD34,  in
 
 
 
 
 
 
 
 B 
 C Ded co-expression CD 19 and CD33, CD 
tra22 and intraMPO of gated cells. 
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FIGURE 4: FISH analysis of case 2 showed presence of BCR-ABL fusion gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Normal patient 
2. Patient 
10. negative control 
11. K562 (positive 
control for CML) 
 
FIGURE 5: Molecular analysis by RT-PCR of case 2 showed presence of major BCR-ABL 
fragment. 
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DISCUSSION 
 
Biphenotypic acute leukaemia (BAL) is a 
form of acute leukaemia of ambiguous 
lineage.  It is a rare entity which is difficult 
to define previously, due to lack of 
consistent diagnostic criteria. The 
characterisation of these disease based on 
morphology alone can be difficult. Blasts 
are often undifferentiated, with no 
distinguishing characteristics. However, 
some cases have been described based 
on the detection of two distinct populations 
of blasts which vary in size. Our two cases 
showed two distinct populations of blasts 
morphologically. The larger blast cells with 
moderate to abundant cytoplasm are 
positive for peroxidase stain and the 
smaller blast cells showing scanty 
cytoplasm, are negative for peroxidase 
stain.   
 Immunophenotyping is the most 
important diagnostic tool in characterizing 
BAL. Diagnostic criteria have been defined 
including those outlined by EGIL (Bene, 
M.C. et al 1995) and WHO (Brunning RD et 
al 2001).  The diagnosis is based on a 
scoring system for markers proposed by 
the EGIL, which defines the minimum 
number of phenotypic characteristics 
necessary to be considered true 
biphenotypia. Patients who do not meet 
these criteria will be diagnosed as either 
AML with lymphoid aberrant markers or 
ALL with myeloid aberrant markers. 
Markers that have been used and 
considered to be most specific to 
differentiate the three cell lines are shown 
in Table 2. Each marker has a different 
score. The score encompasses the number 
and degree of specificity of the markers 
expressed by the leukaemic cells. The 
diagnostic criteria are (i) there should be at 
least a score of 2 from each lineage, and (ii) 
both myeloid and lymphoid markers are 
expressed on the same cells in order to 
diagnose BAL. This is to differentiate 
biphenotypic acute leukaemia from 
bilineage acute leukaemia.  In these two 
cases, the blast cells expressed intra CD22, 
and intra MPO which fulfilled criteria (i) and 
the co-expression of CD 19 and CD 33, CD 
13 and CD 10 in both cases fulfilling criteria 
(ii) which confirmed the diagnosis of BAL. 
In contrast, bilineage acute leukaemia has 
two distinct population of leukaemic cells. 
The larger cells will express myeloid 
markers while the smaller cells will express 
B or T-lymphoid markers. Previous studies 
of BAL have suggested that these 
leukaemias may arise by malignant 
transformation of a pluripotent stem cell. 
The finding of a significantly greater 
percentage of biphenotypic cases with 
CD34 expression compared to non-
biphenotypic cases in a study done by 
Legrand O et al (1998), supports the 
concept that this transformation process 
occurs at a step close to the haemopoietic 
progenitor cell. In the same study, the 
percentage of BAL patients with 
unfavourable karyotype was higher 
compared to AML (60% versus 20%). The 
high percentage of unfavourable 
karyotypes especially abnormalities of 
chromosome 11q23 and t(9;22) has been 
shown by a few studies (Carbonell et al 
1996, Hanson et al 1993). One of the 
patients had an unfavourable karyotype, 
the Philadelphia chromosome, and 
molecular analysis also showed presence 
of BCR-ABL gene. The study by Legrand O 
et (1998) al also showed that most BAL 
patients have P-glycoprotein (Pgp) 
overexpression which correlates with poor 
treatment outcome. Treatment outcome of 
BAL with standard AML protocol has been 
proven to be unfavourable and yet there 
are no standard induction protocol for BAL; 
even those patients who attained remission 
has a higher risk of relapse. The majority of 
the patients received chemotherapy for 
AML and once the patients attained 
morphological remission, upfront stem cell 
transplantation will offer a better outcome. 
Both of our patients received the AML 
induction regime; patient 1 went into 
marrow remission and was planned for 
allogenic peripheral blood stem cell 
transplantation. Unfortunately, there was  
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unfavourable karyotypes, overexpression 
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Therefore, more studies on the induction 
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important not only to improve the treatment 
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adverse effects of the treatment protocols. 
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